Selpercatinib + Cabozantinib + Vandetanib
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Medullary Thyroid Cancer
Conditions
Medullary Thyroid Cancer
Trial Timeline
Feb 11, 2020 → Nov 1, 2027
NCT ID
NCT04211337About Selpercatinib + Cabozantinib + Vandetanib
Selpercatinib + Cabozantinib + Vandetanib is a phase 3 stage product being developed by Eli Lilly for Medullary Thyroid Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04211337. Target conditions include Medullary Thyroid Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04211337 | Phase 3 | Active |
Competing Products
9 competing products in Medullary Thyroid Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selpercatinib | Eli Lilly | Phase 1/2 | 41 |
| Pralsetinib + Cabozantinib + Vandetanib | Roche | Phase 3 | 77 |
| • TF2 and 68 Ga-IMP-288 | Gilead Sciences | Phase 1/2 | 40 |
| Caprelsa | Sanofi | Pre-clinical | 22 |
| Vandetanib 300mg | Sanofi | Phase 1/2 | 40 |
| Vandetanib | Sanofi | Phase 3 | 76 |
| vandetanib + omeprazole + ranitidine | Sanofi | Phase 1 | 32 |
| Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsule | Exelixis | Approved | 82 |
| cabozantinib | Exelixis | Pre-clinical | 20 |